GYKI 16084
Alternative Names: UrofluxLatest Information Update: 11 Aug 2011
At a glance
- Originator IVAX Drug Research Institute
- Class Pyridazines; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 24 Feb 2004 IVAX has completed a phase II trial in Benign prostatic hyperplasia in Hungary
- 18 Jun 2001 Phase-II clinical trials for Benign prostatic hyperplasia in Hungary (Unknown route)
- 14 Jan 2000 Phase-I clinical trials for Benign prostatic hyperplasia in Hungary (Unknown route)